Robot-Assisted versus Open Pancreatoduodenectomy: Identifying Perioperative Anesthetic Factors associated with Postoperative Morbidity. A retrospective cohort study.

Antoon van den Enden (✉ a.vandenenden@erasmusmc.nl)
Erasmus MC  https://orcid.org/0000-0003-2449-8504

Maya Vereen
Erasmus MC

Bas Groot Koerkamp
Erasmus MC

Markus Klimek
Erasmus MC

Research

Keywords: Robotic Surgery, Pancreatoduodenectomy, Pancreatic Surgery, Minimal-Invasive Surgery, Perioperative management, Postoperative morbidity

Posted Date: October 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-958954/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Robot-assisted pancreatoduodenectomy (RAPD) poses several challenges concerning perioperative anesthetic guidance compared to open pancreatoduodenectomy (OPD), e.g. combined pneumoperitoneum with reversed-Trendelenburg positioning. The primary objective of this observational study is to specify these anesthetic differences of RAPD versus OPD and secondly to identify independent anesthetic factors associated with patient morbidity following RAPD.

Methods

All consecutive patients who underwent either RAPD or OPD between 2017 and 2018 were included for analysis. Patient records were screened for intraoperative vasopressor and fluid administration as well as for results of perioperative arterial blood gas analysis. Variables were compared for the groups RAPD versus OPD, major morbidity following RAPD versus non-major morbidity following RAPD (resp. Clavien-Dindo score ≥ III vs. < III) and high versus low intraoperative blood loss during RAPD. Perioperative factors associated with major postoperative morbidity (Clavien-Dindo ≥ III) were identified using a logistic regression model.

Results

N=64 RAPD and n=62 OPD patients were included for retrospective analysis. RAPD was associated with higher administration of intraoperative norepinephrine (9.5% of operative time vs. 0% in OPD, p=0.005) and a higher net intraoperative fluid balance (2497.6 vs. 1572.3 ml, p<0.001). During OPD, patients received more frequent and higher doses of colloid fluids compared to RAPD (79.0% vs. 51.6%, p<0.001, median 1000.0 vs. 500.0 ml, p<0.001). Colloid administration during surgery and hyperlactatemia 12 hours postoperatively were associated with major morbidity after RAPD (OR 5.06, 95% CI 1.49-17.20, p=0.009 and OR 3.18, 95% CI 1.01-9.91, p=0.047, respectively).

Conclusions

RAPD is a challenging procedure for the anesthesiologist, e.g. considering a higher demand for vasopressors. Inotropic/vasopressor administration as well as the intraoperative fluid balance are associated with (major) morbidity following RAPD. However, it remains unclear whether and in which direction a causal relationship exists.

Trial registration: Not applicable.

Background

The robot-assisted approach for pancreatoduodenectomy was first described in 2003 by Giulianotti et al. and has gained momentum as an established minimally invasive technique for pancreatoduodenectomy
surgery [1]. Various cohort studies already compared surgical outcomes of robot-assisted pancreatoduodenectomy (RAPD) with conventional open pancreatoduodenectomy (OPD). Despite increased surgical times, RAPD is characterized by lower intraoperative blood loss with equal postoperative mortality and similar oncological outcome [2–4]. Although the surgical feasibility of RAPD is extensively reported in literature, little is known about perioperative anesthetic concerns of the robotic approach and how perioperative anesthetic factors affect postoperative outcome.

Determining optimal intraoperative fluid regimens during abdominal surgery in relation to postsurgical morbidity is part of ongoing scientific debate. The 2018 RELIEF trial described an association between a more restrictive intraoperative net fluid balance (median 3.7 liters) and an increased rate of kidney injury following major abdominal surgery [5]. However, Grant et al. reported no differences in postoperative major morbidity after randomizing between either a net liberal (12 ml kg/hr) versus net restrictive (6 ml kg/h) intraoperative fluid balance for pancreatic surgery (irrespective of the surgical approach) [6]. RAPD presents several specific challenges concerning the perioperative anesthetic guidance. The patient is exposed to pneumoperitoneum, reversed-Trendelenburg positioning during the majority of surgical time, increasing central venous pressure, expected higher blood carbon dioxide levels and decreasing cardiac output [7–9]. We therefore hypothesize differences between RAPD and OPD in perioperative demands for vasopressor and fluid administration.

The primary objective of this retrospective cohort study is to evaluate perioperative anesthetic differences of RAPD versus OPD. Secondly, this study aims to identify independent anesthetic factors associated with patient morbidity following RAPD.

**Methods**

The Medical Ethics Committee approved a waiver for informed consent on February 14th 2019 (MEC-2019-0090, Medical Ethics Committee, Erasmus MC University Hospital, P. Box 2040, 3000 CA, Rotterdam, the Netherlands), given the retrospective nature of this observational study. All consecutive patients who underwent either RAPD or OPD between January 1st 2017 and December 31st 2018 were included for analysis. RAPD has been performed in our center (tertiary referring hospital for pancreatic diseases) since January 2017. All procedures were undertaken by a dedicated team of two pancreatic surgeons or a pancreatic surgeon together with a pancreatic surgical fellow. RAPD was executed using the Da Vinci Model S robotic surgical device, which was later switched to the Model Xi (Intuitive Surgical Inc., Sunnyvale, CA, USA). OPD was performed by or under direct supervision of three experienced consultant pancreatic surgeons. Several consultant anesthesiologists were involved in both surgical modalities. Patients were assigned to RAPD based on patient preference and availability of both the robot and the robotic surgical team, the sole exclusion criterion for RAPD was locally advanced pancreatic cancer.

RAPD was characterized as full-robotic surgery, meaning both the resection and the reconstruction phase were conducted in a robotic fashion. A central venous catheter was incidentally inserted based on the anesthesiologist’s discretion. All patients were postoperatively admitted to a High Dependency Unit (HDU)
or incidentally to an Intensive Care Unit (ICU). Protocols for postoperative management were identical for HDU and ICU. Standard postoperative analgesic regimen comprised paracetamol (1000mg 4 times daily) and naproxen (750mg 3 times daily). OPD was preferably performed under additional epidural analgesia (routinely using ropivacaine 0.2% combined with sufentanil 1 µg/ml). For RAPD a patient-controlled analgesia (PCA) device (morphine based) was used for postoperative analgesia. Once oral intake was possible again, epidural or PCA analgesia was if necessary converted to oral oxycodone.

Digital patient records were reviewed for patient demographics, intra- and postoperative management and postoperative morbidity. Extracted baseline data included age, sex, body mass index (BMI) and medical history (comprising diabetes mellitus, any pulmonary, cardiac or vascular disease, any history of cerebrovascular accident (CVA) or transient ischemic attack (TIA), hypertension or prior kidney or liver failure). Besides, records were reviewed regarding any history of previous malignancy, abdominal as well as non-abdominal surgery or neoadjuvant chemotherapy. Baseline comorbidity was graded according to the American Society of Anesthesiologist's (ASA) score and Charlson Comorbidity Index (CCI) [10]. Baseline hemoglobin (Hb), platelet count, estimated glomerular filtration rate (e-GFR) and levels of albumin, total bilirubin, creatinine and tumor-marker CA 19-9 were also extracted from patient records.

According to our center's protocol, norepinephrine (NE) was routinely used as first choice perioperative vasopressor. Perioperative anesthesia records were screened for the NE dose on start and end of surgery as well as the amount of times NE dose perioperative exceeded 0.2 µg kg/min (considered the cut-off for the administration of NE over a central instead of peripheral intravenous cannula). The amount of times NE dosage exceeded 0.2 µg kg/min was expressed as time span in minutes and as percentage of operating room time (time between entering versus leaving the surgical theatre). The operative time was defined as the time interval between skin incision and wound closure, time to detubation as the time interval between wound closure and removal of the endotracheal tube.

Fluid balances, including the necessity of erythrocyte transfusion, were studied up to 24 hours following surgery. Types of intravenous fluid used were NaCl 0.9% (Baxter, Deerfield, United States of America) and Sterofundin ® (Braun, Melsungen, Germany) as crystalloids, Voluven ® and Volulyte ® (Hydroxyethylstarch 130/0.4, Fresenius Kabi, Bad Homburg vor der Höhe, Germany) as colloids. Besides, arterial blood gas (ABG) analyses (including blood pH, partial CO₂ (pCO₂) pressure, lactate and Hb count) were studied at 3 points in time: first available sample results during surgery, first available results upon HDU/ICU admission and first available results after a minimum of 12 hour HDU/ICU admission. The perioperative pCO₂ levels were subsequently compared to the corresponding end tidal (et) CO₂ level.

Patient records were screened for the total hours of postoperative HDU/ICU stay and the rate of prolonged HDU/ICU admission, the latter defined as a HDU/ICU stay exceeding 24 hours. The length of postoperative hospital stay was counted in days starting from the first day following surgery. Postoperative morbidity was assessed 90 days after surgery using the Clavien Dindo (CD) morbidity score as well as the Comprehensive Complication Index [11, 12]. Major morbidity was defined as a CD score ≥ III. Kidney failure was graded according to European Society of Anesthesiologists’ (ESA)
European Perioperative Clinical Outcome (EPCO) standards [13]. Pain scores, expressed as Numeric Rating Scale (NRS), were analyzed on postoperative days 1 and 3. Mortality rates were studied on postoperative days 30 and 90.

Baseline and perioperative variables were analyzed for RAPD versus OPD, RAPD patients suffering major postoperative morbidity (CD $\geq$ III) vs. absence of major postoperative morbidity (CD < III) and RAPD patients above versus below median intraoperative blood loss (high and low intraoperative blood loss, respectively). Normal distribution of data was assessed using a combination of visual inspection of histograms and Q-Q plots and the Shapiro-Wilk test. Numerical data were presented as mean (standard deviation, SD) or median (interquartile range, IQR), as appropriate. Categorical data were presented with frequencies and percentages. An independent sample T-test or Mann-Whitney U-test was performed in comparing numerical data, a $\chi^2$ or Fisher's exact test in categorical data. In order to identify independent predictors of major morbidity following RAPD (CD $\geq$ III), a logistic regression model was constructed using a backward stepwise approach. Baseline and perioperative variables showing a significant difference between minor (CD < III) versus major (CD $\geq$ III) morbidity after RAPD and of suspected clinical relevance in predicting major morbidity after RAPD were included in the regression model. Results herein were presented as odds ratio (OR) with corresponding 95% confidence interval (CI). Throughout the study two-tailed P-values of < 0.05 were considered statistically significant. Statistical analysis was carried out using IBM SPSS Statistics (version 24.0, Armonk, NY, USA; IBM Corp.).

Results

126 consecutive patients were included in this study during the two-year inclusion period (n=64 RAPD, n=62 OPD).

RAPD vs. OPD

The only significant difference in baseline patient characteristics was a lower baseline hemoglobin level for OPD (12.6 vs. 13.2 g/dl, p=0.049) (Table 1, additional file 1). Operative time was 441.5 min. in RAPD compared to 318.0 min. in OPD (p<0.001, Table 2, additional file 2). No RAPD procedures were converted to OPD. Net intraoperative fluid balance was higher in RAPD (2497.6 vs. 1572.3 ml in OPD, p<0.001). OPD patients more frequently and quantitatively received colloids compared to RAPD patients (79.0% vs. 51.6%, p<0.001, median 1000.0 vs. 500.0 ml, p<0.001). Average intraoperative blood loss was 250.0 ml for RAPD compared to 1150.0 ml for OPD (p<0.001) with an intraoperative erythrocyte transfusion rate of 6.3% (4/64) for RAPD compared to 30.6% (19/62) for OPD (p<0.001). Within the RAPD group, intraoperative Hb levels were higher during surgery, upon HDU/ICU admission and after a minimum of 12 hour of HDU/ICU admission (12.6 vs. 11.9 g/dl, p=0.017, 12.6 vs. 11.3 g/dl, p<0.001 and 12.1 vs. 11.0 g/dl, p<0.001, respectively).
Table 1
Demographic and baseline details for RAPD and OPD patients

| Variables                        | RAPD vs. OPD | Post-RAPD morbidity |  |
|----------------------------------|--------------|----------------------|---|
|                                  | RAPD (n=64)  | OPD (n=62)           | P  |
|                                  |              |                      | RAPD without major morbidity (CD < III, n=36) | RAPD with major morbidity (CD ≥ III, n=28) | P  |
| Age (yr)                         | 67.8 ± 9.8   | 65.5 ± 10.1          | 0.188 | 66.8 ± 9.7 | 69.1 ± 9.9 | 0.340 |
| Sex (M:F)                        | 1.0:0.9      | 1.0:0.9              | 0.424 | 1.0:1.0    | 1.0:0.9    | 0.806 |
| BMI (kg/m²)                      | 25.0 (18.9-37.9) | 24.6 (16.7-40.7) ² | 0.179 | 25.9 ± 5.0 | 26.0 ± 3.3 | 0.909 |
| Medical history                  |              |                      |     |            |            |      |
| Diabetes mellitus                | 17 (26.6)    | 22 (35.5)            | 0.337 | 12 (33.3)  | 5 (17.9)   | 0.254 |
| Pulmonary disease                | 13 (20.3)    | 9 (14.5)             | 0.484 | 7 (19.4)   | 6 (21.4)   | 1.000 |
| Cardiac disease                 | 17 (26.6)    | 15 (24.4)            | 0.839 | 9 (25.0)   | 8 (28.6)   | 0.782 |
| Vascular disease                | 2 (3.1)      | 5 (8.1)              | 0.269 | 1 (2.8)    | 1 (3.6)    | 1.000 |
| CVA or TIA                      | 5 (7.8)      | 6 (9.7)              | 0.761 | 3 (8.3)    | 2 (7.1)    | 1.000 |
| Hypertension                    | 28 (43.8)    | 25 (40.3)            | 0.721 | 11 (30.6)  | 17 (60.7)  | 0.023 |
| Kidney or liver failure         | 10 (15.6)    | 10 (16.1)            | 1.000 | 4 (11.1)   | 6 (21.4)   | 0.312 |
| Previous malignancy             | 19 (29.7)    | 18 (29.0)            | 1.000 | 9 (25.0)   | 10 (35.7)  | 0.256 |
| Previous abdominal surgery      | 35 (54.7)    | 36 (58.1)            | 0.723 | 21 (58.3)  | 14 (50.0)  | 0.615 |
| Previous non-abdominal surgery  | 41 (64.1)    | 43 (69.4)            | 0.574 | 22 (61.1)  | 19 (67.9)  | 0.610 |
| ASA                              |              |                      |     |            |            |      |
| I                                | 8 (12.5)     | 4 (6.9)              | 0.543 | 6 (16.7)   | 2 (7.1)    | 0.460 |
| II                               | 45 (70.3)    | 41 (70.3)            | 25 (69.4) | 20 (71.4)  | 0.460 |
| Variables                      | RAPD vs. OPD | Post-RAPD morbidity |
|-------------------------------|--------------|----------------------|
|                               | RAPD (n=64)  | OPD (n=62)           | P       | RAPD without major morbidity (CD < III, n=36) | RAPD with major morbidity (CD ≥ III, n=28) | P |
| III                           | 11 (17.2)    | 13 (22.4) 4          | 5 (13.9) | 6 (21.4)                                              |                                          |   |
| IV                            | 0            | 0                    | 0        | 0                                                    |                                          |   |
| Charlson Comorbidity Index    |              |                      |          |                                                      |                                          |   |
| Score                         | 5.4 ± 2.0    | 5.4 ± 1.9            | 0.900    | 5.1 ± 1.9                                           | 5.8 ± 2.0                                 | 0.161 |
| Charlson = 0                  | 0            | 0                    |          |                                                      |                                          |   |
| Charlson = 1-3                | 12 (18.8)    | 10 (16.1)            | 0.332    | 8 (22.2)                                           | 4 (14.3)                                  | 0.492 |
| Charlson = 4-6                | 34 (53.1)    | 35 (56.5)            |          | 18 (50.0)                                           | 16 (57.1)                                 |   |
| Charlson = 7                  | 18 (28.1)    | 17 (27.4)            |          | 10 (27.8)                                           | 8 (28.6)                                  |   |
| Preoperative chemotherapy      | 4 (6.3)      | 11 (17.7)            | 0.057    | 2 (5.6)                                             | 2 (7.1)                                   | 0.593 |
| Baseline laboratory           |              |                      |          |                                                      |                                          |   |
| Hemoglobin level (mmol/L)     | 8.2 ± 0.9    | 7.8 ± 1.0            | 0.049    | 8.0 ± 0.9                                           | 8.4 ± 0.8                                 | 0.116 |
| Platelet count (x 10^9/L)     | 266 ± 83     | 293 ± 78             | 0.063    | 264 (114-556)                                        | 236 (135-402)                             | 0.365 |
| e-GFR (ml/min/1.73 m^2)       | 81.3 ± 18.1  | 82.9 ± 17.5          | 0.610    | 84.4 ± 17.2                                        | 77.3 ± 18.7                              | 0.123 |
| Albumin level (g/L)           | 42.1 ± 7.2   | 41.8 ± 4.6           | 0.757    | 41.0 (24.0-50.0) 1                                  | 42.0 (32.0-75.0) 1                       | 0.564 |
| Total bilirubin level (umol/L)| 11.5 (3.0-214.0) | 9.0 (3.0-208.0) 1       | 0.218    | 12.5 (3.0-214.0)                                    | 10.5 (5.0-51.0)                          | 0.542 |
| Creatinine level (umol/L)     | 77.0 ± 23.7  | 75.4 ± 18.8          | 0.675    | 73.5 ± 17.3                                        | 81.4 ± 29.7                              | 0.216 |
| Variables | RAPD vs. OPD | Post-RAPD morbidity |
|-----------|-------------|---------------------|
|           | RAPD (n=64) | OPD (n=62) | P | RAPD without major morbidity (CD < III, n=36) | RAPD with major morbidity (CD ≥ III, n=28) | P |
| Ca 19-9 (kU/L) | 33.0 (1.0-5146.0) | 29.0 (1.0-7408.0) | 0.880 | 35.0 (1.0-5146.0) | 33.0 (1.0-1908.0) | 0.946 |

Values are presented as number (proportion) or depending on normality distribution of cases as mean ± SD or median (interquartile range). \( X^n \) where \( n \) represents the number of missing cases. ASA, American Society of Anesthesiologists Classification; BMI, Body Mass Index; CD, Clavien Dindo; CVA, Cerebro Vascular Accident; e-GFR, Estimated Glomerular Filtration Rate; OPD, Open Pancreatoduodenectomy; RAPD, Robot-Assisted Pancreatoduodenectomy; TIA, Transient Ischemic Attack.
Table 2
Perioperative anesthesia-related factors, RAPD vs. OPD

| Variables                                      | RAPD vs. OPD |          |          | P      |
|------------------------------------------------|--------------|----------|----------|--------|
|                                                | RAPD (n=64)  | OPD (n=62)|          |        |
| Operating room time (min)                      | 513.5 (377.0-836.0) | 392.5 (240.0-802.0) | <0.001 |
| Operative time (min)                           | 441.5 (326.0-756.0) | 318.0 (188.0-753.0) | <0.001 |
| Intraoperative fluid balance                   |              |          |          |        |
| Net positive fluid balance (ml)                | 2497.6 (544.0-5535.0) | 1572.3 (50.0-25925.2) | <0.001 |
| Crystalloid dose (ml)                          | 2100.0 (51.0-5137.0) | 1896.0 (0.0-8337.4) | 0.069  |
| Colloid dose (ml)                              | 500.0 (0.0-2000.0) | 1000.0 (0.0-5700.0) | <0.001 |
| Colloid administration                         | 33.0 (51.6) | 49.0 (79.0) | <0.001 |
| Blood loss (ml)                                | 250.0 (0.0–2500.0) | 1150.0 (0.0-11585.0) | <0.001 |
| Intraoperative erythrocyte transfusion         | 4 (6.3) | 19 (30.6) | <0.001 |
| NE regimen                                     |              |          |          |        |
| NE dose on surgery’s start (ug/kg/min)         | 0.05 (0.00-0.20) | 0.03 (0.00-0.72) | 0.021  |
| NE dose on surgery’s end (ug/kg/min)           | 0.06 (0.00-0.38) | 0.06 (0.00-0.80) | 0.821  |
| NE dose > 0.2 ug/kg/min (min)                  | 1 (0-5) | 0 (0-3) | 0.005 |
| Time span NE dose > 0.2 ug/kg/min (min)        | 4.1 (0.0-610.0) | 0.0 (0.0-393.0) | 0.002 |
| Operative time NE dose > ug/kg/min (%)         | 9.5 (0.0-96.2) | 0.0 (0.0-56.5) | 0.005 |
| First arterial BGA during surgery              |              |          |          |        |
| Blood pH                                       | 7.32 ± 0.06 | 7.35 ± 0.06 | <0.001 |
| Partial CO₂ pressure (kPa)                     | 6.2 (4.3-24.2) | 5.6 (4.5-7.1) | <0.001 |
| Corresponding end-tidal CO₂ (kPa)              | 5.0 ± 0.6 | 4.7 ± 0.3 | 0.001 |
| Lactate level (mmol/L)                         | 0.7 (0.3-1.9) | 0.7 (0.3-2.7) | 0.884 |
On average, NE administration during the start of surgery was higher in RAPD (0.05 vs. 0.03 µg kg/min in OPD, p=0.021). During the intraoperative course of RAPD, NE dosage exceeded 0.2 µg kg/min more frequently compared to OPD with a median time span of 48 vs. 0 min (p=0.002) equaling 9.5 vs. 0 percent of operating room time (p=0.005). RAPD was characterized by a more acidic blood pH during surgery (7.32 vs. 7.35 in OPD, p=0.021) with high pCO2 pressures and corresponding etCO2 levels (6.2 vs. 5.6 kPa, p<0.001 and 5.0 vs. 4.7 kPa, p=0.001, respectively). A similar trend was observed in RAPD patients upon HDU/ICU arrival (arterial blood pH 7.33 vs. 7.35 in OPD, p=0.013 and pCO2 5.8 vs. 5.5 kPa, p=0.002, Table 2, additional le 2).

No differences were observed in major morbidity (CD ≥ III) following RAPD versus OPD (28/64, 43.8% in RAPD vs. 33/62, 53.2% in OPD, p=0.373, Table 3). Average Comprehensive Complication Index was 32.7 for RAPD vs. 49.9 in OPD (p=0.012). Postoperative acute kidney injury was present in 9/64 (14.5%) of RAPD patients vs. 6/62 (9.7%) of OPD patients (p=0.583). Six patients entered the procedure with pre-existing renal impairment (e-GFR < 60 ml/min, n=3 in RAPD and n=3 in OPD): no further deterioration of kidney injury was observed in any of these patients. Average NRS on postoperative day 1 was 3 for RAPD
compared to 1 for OPD (p<0.001). On postoperative day 3, average NRS was 2 for both RAPD and OPD (p=0.894).

Table 3
Postoperative outcome after RAPD vs. OPD

| Variables                             | RAPD (n=64) | OPD (n=62) | P     |
|---------------------------------------|-------------|------------|-------|
| Time to detubation (min)              | 32.0 (0.0-931.0) | 21.0 (1.0-21714.0) | 0.381 |
| Stay HCU/IDU (hours)                  | 19.5 (14.6-97.4) | 21.6 (15.6-478.4) | <0.001 |
| Prolonged HDU/ICU admission           | 5 (7.8) | 12 (19.7) | 0.069 |
| Hospital stay (days)                  | 11.5 (4.0-61.0) | 14.5 (6.0-200.0) | 0.277 |
| Comprehensive Complication Index      | 32.7 (0.0-100.0) | 49.9 (8.7-100.0) | 0.012 |
| CD morbidity rates                    |             |            |       |
| Grade III                             | 20 (31.1) | 23 (37.1) | 0.574 |
| Grade IIIA                            | 15 (23.4) | 14 (22.6) | 1.000 |
| Grade IIIB                            | 5 (7.8) | 9 (14.5) | 0.268 |
| Grade IV                              | 8 (12.5) | 10 (16.1) | 0.617 |
| Grade IVA                             | 3 (4.7) | 4 (6.5) | 0.715 |
| Grade IVB                             | 5 (7.8) | 6 (9.7) | 0.761 |
| => Grade III                          | 28 (43.8) | 33 (53.2) | 0.420 |
| Acute Kidney failure                  | 9 (14.5) | 6 (9.4) | 0.583 |
| 30-day mortality                      | 1 (1.6) | 2 (3.2) | 0.616 |
| 90-day mortality                      | 5 (7.8) | 4 (6.5) | 1.000 |
| NRS Postoperative day 1               | 3 (0-7) | 1 (0-7) | <0.001 |
| NRS Postoperative day 3               | 2 (0-7) | 2 (0-5) | 0.894 |

Values are presented as number (proportion) or depending on normality distribution of cases as mean ± SD or median (interquartile range). X: where represents the number of missing cases. CD, Clavien Dindo; HDU, High Dependency Unit; ICU, Intensive Care Unit; NRS, Numeric Rating Scale; OPD, Open Pancreatoduodenectomy; RAPD, Robot Assisted Pancreatoduodenectomy.

Postoperative morbidity after RAPD: major (CD ≥ III) vs. non-major (CD < III)

A higher rate of baseline hypertension was observed in the RAPD subgroup with major postoperative morbidity (17/28, 60.7% vs. 11/36, 30.6%, p=0.023, Table 1). Median intraoperative colloid administration
and blood loss were higher in the RAPD group with major postoperative morbidity (500.0 vs. 0.0 ml, p=0.002 and 350.0 vs. 200.0 ml, p=0.047, respectively, Table 4, additional file 3). Average NE dose was higher at the end of surgery for the RAPD subgroup with major postoperative morbidity (0.09 vs. 0.04 µg kg/min, p=0.726). Upon HDU/ICU admission, lower arterial blood pH as well as higher lactate levels were observed in the RAPD subgroup with major postoperative morbidity (7.32 vs. 7.34, p=0.017 and 1.7 vs 1.3 mmol/l, in the RAPD subgroup without major postoperative morbidity, respectively). A similar trend was observed after a minimum of 12 hour HDU/ICU stay (7.37 vs. 7.39, p=0.016 and 1.4 vs. 0.9 mmol/l, respectively). Hospital stay was more than doubled in the patients with major postoperative morbidity compared to patients (18.0 vs. 7.0 days, p<0.001, Table 5). Within 90 days following surgery, n=2 RAPD patients deceased due to early recurrence of malignant disease (one in both RAPD subgroups).
Table 4  
Perioperative anesthetic factors in RAPD

| Variables                              | RAPD (n=64)          | Post-RAPD morbidity | Intraoperative blood loss (RAPD) |
|----------------------------------------|----------------------|---------------------|----------------------------------|
|                                        | RAPD with major morbidity (CD ≥ III, n=28) | RAPD without major morbidity (CD < III, n=36) | High (≥ 250 ml, n=33) | Low (< 250 ml, n=31) | P |
| Operating room time                    | 513.5 (377.0-836.0)  | 527.5 (397.0-749.0) | 513.5 (377.0-836.0) | 0.690 | 580.0 (397.0-750.0) | 478.0 (377.0-836.0) | 0.001 |
| Operative time                         | 441.5 (326.0-756.0)  | 463.5 (353.0-691.0) | 441.5 (326.0-756.0) | 0.671 | 516.0 (353.0-691.0) | 410.0 (326.0-756.0) | 0.001 |
| Intraoperative fluid balance           |                      |                     |                                 |     |                   |                   |        |
| Net positive fluid balance (ml)        | 2497.6 (544.0-5535.0) | 2777.1 ± 1046.9 1   | 2688.0 ± 806.3               | 0.704 | 3057.0 (544.0-5535.0) | 2288.9 (1525.6-4346.9) | 0.012 |
| Crystalloid dose (ml)                  | 2100.0 (51.0-5137.0) | 2267.4 ± 1110.4 1   | 2294.4 ± 702.2               | 0.906 | 2478.7 ± 1048.7 1   | 2080.6 ± 51.6         | 0.076 |
| Colloid dose (ml)                      | 500.0 (0.0-2000.0)   | 500.0 (0.0-2000.0) 1| 0.0 (1.0-1000.0)             | 0.002 | 500.0 (0.0-2000.0) 1| 0.0 (0.0-1250.0)      | <0.001 |
| Colloid administration                 | 33.0 (51.6) 1        | 20 (71.4) 1         | 13 (36.1)                     | 0.005 | 25 (75.8) 1         | 8 (25.8)           | <0.001 |
| Blood loss (ml)                        | 250.0 (0.0-2500.0)   | 350.0 (0.0-2500.0)  | 200.0 (30.0-2000.0)           | 0.047 | 500.0 (250.0-2500.0) | 150.0 (0.0-200.0)   | <0.001 |
| Intraoperative erythrocyte transfusion | 4 (6.3) 1            | 2 (7.1) 1           | 2 (5.6)                       | 1.000 | 4 (12.1) 1          | 0                   | 0.113 |
| NE regimen                             |                      |                     |                                 |     |                   |                   |        |
| NE dose on surgery’s start (ug/kg/min) | 0.05 (0.00-0.20) 2   | 0.05 (0.01-0.20) 1   | 0.05 (0.00-0.20) 1            | 0.472 | 0.05 (0.00-0.19) 2  | 0.05 (0.00-0.20) 2   | 0.692 |
| Variables | RAPD (n=64) | Post-RAPD morbidity | Intraoperative blood loss (RAPD) |
|-----------|------------|---------------------|----------------------------------|
|           | RAPD with major morbidity (CD ≥ III, n=28) | RAPD without major morbidity (CD < III, n=36) | High (≥ 250 ml, n=33) | Low (< 250 ml, n=31) | P |
| NE dose on surgery’s end (ug/kg/min) | 0.06 (0.00-0.38) | 0.09 (0.00-0.22) | 0.04 (0.00-0.38) | 0.726 | 0.09 (0.00-0.38) | 0.04 (0.00-0.25) | 0.518 |
| NE dose > 0.2 ug/kg/min (min) | 1 (0-5) | 1 (0-5) | 1 (0-3) | 0.471 | 1 (0-4) | 1 (0-5) | 0.374 |
| Time span NE dose > 0.2 ug/kg/min (min) | 4.1 (0.0-610.0) | 133.0 (0.0-610.0) | 22.5 (0.0-550.0) | 0.262 | 134.0 (0.0-600.0) | 15.0 (0.0-610.0) | 0.283 |
| Operative time NE dose > ug/kg/min (%) | 9.5 (0.0-96.2) | 20.4 (0.0-96.2) | 5.0 (0.0-9.1) | 0.298 | 20.8 (0.0-86.2) | 4.0 (0.0-96.2) | 0.431 |

First arterial BGA during surgery

| Blood pH | 7.32 ± 0.06 | 7.34 ± 0.06 | 7.31 ± 0.06 | 0.135 | 7.31 ± 0.06 | 7.33 ± 0.06 | 0.361 |
| Partial CO₂ pressure (kPa) | 6.2 (4.3-24.2) | 6.1 (4.3-8.1) | 6.3 (5.3-24.2) | 0.681 | 6.3 (4.3-8.4) | 6.1 (5.1-24.2) | 0.695 |
| Corresponding end-tidal CO₂(kPa) | 5.0 ± 0.6 | 5.0 ± 0.7 | 5.0 ± 0.5 | 0.895 | 5.0 (3.9-6.5) | 5.0 (3.9-6.6) | 0.703 |
| Lactate level (mmol/L) | 0.7 (0.3-1.9) | 0.8 (0.3-1.9) | 0.7 (0.4-1.3) | 0.403 | 0.8 (0.3-1.6) | 0.7 (0.4-1.9) | 0.411 |
| Hemoglobin count (mmol/L) | 7.8 ± 0.8 | 7.9 ± 0.8 | 7.8 ± 0.9 | 0.526 | 7.7 ± 0.9 | 8.0 ± 0.8 | 0.180 |

First arterial BGA upon HDU/ICU admission

| Blood pH | 7.33 ± 0.04 | 7.32 ± 0.04 | 7.34 ± 0.04 | 0.017 | 7.33 ± 0.05 | 7.33 ± 0.04 | 0.588 |
| Variables                      | RAPD (n=64) | Post-RAPD morbidity | Intraoperative blood loss (RAPD) |
|-------------------------------|-------------|---------------------|---------------------------------|
|                               |             | RAPD with major morbidity | RAPD without major morbidity | High (≥ 250 ml, n=33) | Low (< 250 ml, n=31) | P    |
|                               |             | (CD ≥ III, n=28)     | (CD < III, n=36)              |                      |                        |      |
| Partial CO₂ pressure (kPa)    | 5.8 (4.7-20.1) | 5.8 (4.8-20.1) | 5.8 (4.6-10.7) | 0.241 | 5.8 (4.7-10.7) | 5.8 (5.0-10.7) | 0.588 |
| Lactate level (mmol/L)        | 1.3 (0.1-6.3) | 1.7 (0.5-6.3) | 1.3 (0.1-6.3) | 0.021 | 1.6 (0.5-3.7) | 1.0 (0.1-3.7) | 0.008 |
| Hemoglobin count (mmol/L)     | 7.8 ± 0.9   | 7.8 ± 0.9   | 7.8 ± 0.9 | 0.874 | 7.5 ± 0.9 | 8.1 ± 0.8 | 0.007 |
| First arterial BGA after ≥ 12 hours HDU/ICU admission |          |                  |                          |                      |                        |      |
| Blood pH                      | 7.39 (7.29-7.48) | 7.37 ± 0.04 | 7.39 ± 0.03 | 0.016 | 7.38 ±0.04 | 7.40 ± 0.04 | 0.131 |
| Partial CO₂ pressure (kPa)    | 5.8 (4.7-7.0) | 5.8 ± 0.5 | 5.6 ± 0.5 | 0.190 | 5.8 (4.8-7.0) | 5.7 (4.9-7.0) | 0.906 |
| Lactate level (mmol/L)        | 1.1 (0.5-2.9) | 1.4 (0.6-2.8) | 0.9 (0.5-2.9) | 0.014 | 1.2 (0.7-2.9) | 1.0 (0.5-2.9) | 0.282 |
| Hemoglobin count (mmol/L)     | 7.5 ± 0.9 | 7.7 (5.2-8.7) | 7.6 (6.1-9.5) | 0.864 | 7.1±0.9 | 7.9 ± 0.7 | <0.001 |

Values are presented as number (proportion) or depending on normality distribution of cases as mean ± SD or median (interquartile range). Xn where n represents the number of missing cases. BGA, Blood Gas Analysis; HDU, High Dependency Unit; ICU, Intensive Care Unit; NE, Norepinephrine; OPD, Open Pancreatoduodenectomy; RAPD, Robot Assisted Pancreatoduodenectomy.
### Table 5
Postoperative outcome after RAPD

| Variable                        | RAPD (n=64) | Post-RAPD morbidity | Intraoperative (RAPD) blood loss |
|---------------------------------|-------------|----------------------|----------------------------------|
|                                 |             | RAPD with major morbidity | RAPD without major morbidity | P  | High (≥ 250 ml, n=33) | Low (< 250 ml, n=31) | P    |
|                                 |             | (CD ≥ III, n=28)     | (CD < III, n=36)               |     | 55.0 (0.0-931.0)     | 22.5 (0.0-185.0)     | 0.327 |
| Time to detubation (min)        | 32.0 (0.0-931.0) | 49.5 (0.0-403.0) 6   | 24.0 (0.0-931.0) 5             | 0.316 | 8               | 3               |       |
| Stay HDU/ICU (hours)            | 11.5 (4.0-61.0) | 20.0 (15.3-97.4)     | 19.1 (14.6-44.0)               | 0.140 | 18.8 (14.0-97.4)     | 19.7 (14.6-44.9)     | 0.122 |
| Prolonged HDU/ICU admission     | 5 (7.8)     | 4 (14.3)             | 1 (2.8)                        | 0.159 | 3 (9.1)            | 2 (6.5)            | 1.000 |
| Hospital stay (days)            | 10.5 (4.0-61.0) | 19.0 (5.0-61.0)     | 8.0 (4.0-37.0)                 | <0.001 | 17.0 (5.0-61.2)     | 9.0 (4.0-48.0)      | 0.002 |
| Comprehensive Complication Index| 32.7 (0.0-100.0) | 64.5 (0.0-100.0)    | 21.8 (0.0-100.0)               | <0.001 | 51.5 (12.2-100.0)   | 24.2 (0.0-99.9)     | <0.001 |
| CD ≥ Grade III                  | 28 (43.8)  | -                    | -                              | -     | 20 (60.6)           | 8 (25.8)           | 0.006 |
| NRS Postoperative day 1         | 3 (0-7) 8   | 3 (0-7) 1           | 2 (0-7) 7                      | 0.248 | 3 (0-7) 3           | 2 (0-7) 5          | 0.255 |
| NRS Postoperative day 3         | 2 (0-7) 9   | 2 (0-7) 3           | 2 (0-4) 6                      | 0.071 | 2 (0-7) 4           | 2 (0-7) 5          | 0.562 |

Values are presented as number (proportion) or median (interquartile range). X^n where n represents the number of missing cases. CD, Clavien Dindo; HDU, High Dependency Unit; ICU, Intensive Care Unit; NRS, Numeric Rating Scale; OPD, Open Pancreatoduodenectomy; RAPD, Robot Assisted Pancreatoduodenectomy.

---

High vs. low intraoperative blood loss in RAPD

Average intraoperative blood loss was 250 ml in RAPD (Table 2, additional file 2), n=33 RAPD procedures were characterized by high (≥ 250 ml) vs. n=31 RAPD procedures with low (< 250 ml) intraoperative blood loss. Both operating room and operative times were longer in the RAPD group with high
intraoperative blood loss (580.0 vs. 487.0 min., p=0.001 and 518.0 vs. 410.0 min., p=0.001, respectively, Table 4, additional file 3). Average NE dose at the end of surgery was higher for the RAPD group with high intraoperative blood loss (0.09 vs. 0.04 µg kg/min in the RAPD group with low intraoperative blood loss). NE-dose tended to exceed 0.2 µg kg/min more frequently in the RAPD group of high intraoperative blood loss (134.0 vs. 15.0 min, p=0.283, and 20.8% vs. 4.0% of operative time, p=0.431). Upon HDU/ICU admission, lactate levels were higher in the RAPD group of high intraoperative blood loss (1.6 vs. 1.0 mmol/l in the RAPD group of low intraoperative blood loss, p=0.008). Length of hospital stay was doubled for the RAPD group of high intraoperative blood loss (16.0 vs. 8.0 days in the RAPD group of low intraoperative blood loss, p=0.002, Table 5). A higher rate of postoperative morbidity was observed in the RAPD group with high intraoperative blood loss (Comprehensive Complication Index of 51.5 vs. 24.2 in the RAPD group with low intraoperative blood loss, p<0.001). Besides, a higher rate of major postoperative morbidity (CD ≥ III) was found in the RAPD group characterized by high intraoperative blood loss (20/33, 60.6% vs. 8/31, 25.8% in the RAPD group of low intraoperative blood loss, p=0.006).

Predictors of major morbidity following RAPD

After performing univariate logistic regression, variables independently associated with major morbidity (CD ≥ III) following RAPD were baseline medical history of hypertension (OR 3.51, 95% CI 1.24-9.92, p=0.018), colloid administration during surgery (OR 5.06, 95% CI 1.69-15.14, p=0.004), lactate level upon HDU/ICU admission (OR 2.47, 95% CI 1.27-4.82, p=0.008) and lactate level after 12 hour HDU/ICU admission (OR 3.66, 95% CI 1.29-10.44, p=0.015, Table 6). After carrying out backward stepwise regression, colloid administration during surgery and lactate level after 12 hour HDU/ICU admission remained independently associated with major morbidity after RAPD (OR 5.06, 95% CI 1.49-17.2, p=0.009 and OR 3.18, 95% CI 1.01-9.91, p=0.047, respectively).
Table 6
Logistic regression analysis: anesthesia-related factors independently associated with major morbidity (CD ≥ III) after RAPD

| Variable                                      | Univariable analysis | Backward stepwise regression |
|-----------------------------------------------|----------------------|------------------------------|
|                                               | OR       | 95% CI        | P   | OR       | 95% CI        | P   |
| Medical history of hypertension               | 3.51     | 1.24 to 9.92  | 0.018 | 3.28     | 0.97 to 11.13 | 0.057 |
| Intraoperative colloid administration         | 5.06     | 1.69 to 15.14 | 0.004 | 5.06     | 1.49 to 17.20 | 0.009 |
| Blood loss during surgery (ml)                | 1.12     | 1.00 to 1.26  | 0.058 |          |                |      |
| Operating room time (min)                     | 1.00     | 1.00 to 1.01  | 0.599 |          |                |      |
| Lactate level in first BGA after HDU/ICU admission (mmol/L) | 2.47     | 1.27 to 4.82  | 0.008 |          |                |      |
| Lactate level in BGA after ≥ 12 hour HDU/ICU admission (mmol/L) | 3.66     | 1.29 to 10.44 | 0.015 | 3.18     | 1.01 to 9.91  | 0.047 |

BGA, Blood Gas Analysis; CI, confidence interval; CD, Clavien Dindo; HDU, High Dependency Unit; ICU, Intensive Care Unit; NE, Norepinephrine; OR, Odds Ratio; RAPD, Robot Assisted Pancreatoduodenectomy.

Discussion

RAPD is characterized by higher perioperative vasopressor administration as well as a higher intraoperative net fluid balance, compared to OPD. However, colloid administration and erythrocyte transfusion were more often used in OPD compared to RAPD. Rates of major postoperative morbidity following surgery (CD ≥ III) were similar for RAPD and OPD. Patients who developed major morbidity (CD ≥ III) after RAPD required vasopressor administration in higher doses and more often received intraoperative colloids than those without major postoperative morbidity. Administration of colloids as well as increased postoperative lactate levels, were independently associated with major morbidity (CD ≥ III) following RAPD.

When interpreting outcomes following RAPD versus OPD, patient-related factors are more likely to affect postoperative morbidity compared to the surgical modality. We report a relatively small portion of patients marked ASA class III and higher (11/64, 17.2% in RAPD and 13/62, 22.4% in OPD), compared to earlier studies reporting percentages up to 43.1 and 82.4% [14, 15]. This discrepancy might suggest an underrating of ASA grading, in contrast with the 2017 strengthened ASA classifications [16]. ASA scores
in our series are however in concordance with recent findings of van Roessel et al., reporting a fraction of 21.8% ASA III patients in a cohort of n=3341 pancreatic surgeries, based on the Dutch Nationwide Pancreatic Cancer Audit data [17, 18]. Van Roessel et al. predicts worse outcome following pancreatectoduodenectomy in patients allocated ASA ≥ III (OR 0.59, 95% CI 0.44-0.80, for achieving ‘optimal outcome’ after pancreatic surgery). In our study ASA class itself was not an individual predictor for postoperative major morbidity (CD ≥ III) as baseline hypertension was (OR 3.51, 95% CI 1.24-9.92). This finding, along with higher vasopressor demands in RAPD, implies as association between elemental hemodynamic and cardiovascular condition and postoperative outcome following RAPD. This observation illustrates the necessity of adequate perioperative cardiovascular risk management, e.g. suggesting lower postoperative morbidity following RAPD in case of optimal baseline antihypertensive therapy, invasive monitoring of circulatory status and prompt intervention in case of any deterioration. However, having a medical history of hypertension might include several other conditional factors posing an increased risk for developing (major) postoperative morbidity (e.g. increased BMI, vascular remodeling or pre-existing renal insufficiency) by itself.

The higher use of intraoperative vasopressors in RAPD versus OPD can be explained by differences in patient positioning (reversed-Trendelenburg in RAPD vs. supine in OPD) as well as exposure to pneumoperitoneum, increasing cardiac afterload and decreasing cardiac output [7–9]. A higher demand for vasopressor administration in RAPD was not necessarily reflected by worse baseline physical condition. Except for the fact that OPD patients more often received neoadjuvant chemotherapy and baseline hemoglobin levels were lower, no differences in baseline medical conditions could be demonstrated between RAPD and OPD patients. Although the intraoperative use of vasopressors was evident, we feel supported by recently published data that the routine insertion of a central venous catheter is not mandatory in neither RAPD nor OPD patients [19, 20].

The 2018 RELIEF Study focused on postoperative outcomes after distinct intraoperative fluid strategies during major abdominal surgery, differentiating between an either restrictive (median crystalloid + colloid 2177 ml) or liberal (median crystalloid + colloid 3500 ml) net intraoperative fluid balance [5]. Whereas no differences were observed in general postoperative outcomes between both fluid approaches, a more liberal intraoperative fluid strategy was associated with lower rates of postoperative acute kidney failure (17/1439, 5.0% for liberal vs. 124/1443, 8.6% for restrictive, p<0.001). In our study, median intraoperative net fluid balance was 2800 ml and 9/64 (14.5%) of RAPD patients suffered from postoperative acute kidney injury. Bannone et al. suggested an association between a more restrictive perioperative fluid balance and an increased risk for developing postoperative pancreatic fistula [21]. On the contrary, the 2019 meta-analysis by Garland et al. reported an OR of 0.54 (95% CI 0.31–0.94) for major morbidity following pancreatectoduodenectomy surgery after adopting a more restrictive intraoperative fluid strategy [22]. The optimal intraoperative fluid regime in pancreatectoduodenectomy remains point of debate: current insights are contradictory and prospective research in this area should distinguish between laparoscopic and open pancreatic surgery.
We observed an association between the intraoperative administration of colloids and development of major morbidity after RAPD (OR 5.06, 95% CI 1.96-15.14, p=0.009). This finding is in accordance with Simões et al., reporting an OR of 1.86 (95% CI 1.03-4.307) for major morbidity following the intraoperative administration of colloids (including n=308 elective surgical procedures for abdominal malignancies, including n=22 pancreatic surgeries) [23]. In our series, 8/31 (25.8%) RAPD patients with low intraoperative blood loss vs. 25/33 (75.8%) RAPD patients with high intraoperative blood loss received colloids during surgery. Of note, it is important to consider who are the patients requiring intraoperative colloid administration. Since colloid fluid administration is an integral part of the treatment in case of major blood loss in our center, the association of intraoperative colloid administration and development of major postoperative morbidity (CD ≥ III) does not necessarily have to reflect a direct causative effect.

During the perioperative course, pH values were lower in RAPD compared to OPD (7.32 vs. 7.35 on beginning of surgery, p=0.021 and 7.33 vs. 7.35 upon HDU/ICU arrival, p=0.013). Differences in pH levels of this magnitude do not reflect clinical relevance. In our series a higher lactate level after a minimal admission of 12 hours on HDU/ICU was associated with major morbidity after RAPD (OR 3.18, 95% CI 1.01-9.91, p=0.047). This is in accordance with De Schryver et al., reporting an OR of 3.58 (95% CI 1.22-10.18, p=0.020) for 6-hour post pancreatic (laparotomic) surgery hyperlactatemia and development of postoperative pancreatic fistula [24]. Average postoperative pain scores during the first postoperative day were higher in RAPD compared to OPD. The reported first postoperative day NRS of 3 in RAPD compared to a NRS of 1 in OPD is of limited clinical relevance and therefore not likely to attribute to major morbidity. Besides, this moderate difference can well be explained by the routine application of additional epidural analgesia in OPD, in accordance with previously reported studies on additional epidural analgesia during pancreatoduodenectomy [25].

Our study has several limitations. First the retrospective single-center study design covering a relatively high, but still limited number of procedures. Due to the limited number of surgeons, the surgical approach was very standardized. This is in contrast to the perioperative anesthetic care, which was provided by several consultant anesthesiologists who followed the available protocols with different levels of adherence. We consider this variability in the anesthesiological approach a mirror of clinical practice and an aspect which deserves special attention in possible prospective trials. Also, although locally advanced pancreatic disease was considered the only exclusion criteria for RAPD, study results could be biased by patient selection for RAPD either OPD surgery.

Conclusions

There are specific differences and challenges regarding the perioperative anesthetic strategy between RAPD and OPD. RAPD is associated with higher levels of vasopressor administration during surgery and net perioperative fluid balance is higher. Contrarily, the levels of colloid and erythrocyte transfusion are higher for OPD compared to RAPD. Baseline hypertension, perioperative colloid administration and
increased lactate levels after surgery are associated with higher rates of major morbidity (CD ≥ III) following RAPD. A more restrictive intraoperative fluid regime has previously been shown to increase postoperative (nephrogenic) morbidity, present evidence is nonetheless contradictory. Current data is insufficient to make specific recommendations to optimal perioperative anesthetic guidance in RAPD. However, perioperative hemodynamic management including preoperative optimization and intraoperative fluid- and vasopressor- strategy are suggested to influence postoperative morbidity and should be the focus of future prospective studies.

Abbreviations

ASA = American Society of Anesthesiologists
BGA = Blood Gas Analysis
BMI = Body Mass Index
CCI = Charlson Comorbidity Index
CD = Clavien Dindo
CI = Confidence Interval
CVA = Cerebro Vascular Accident
e-GFR = Estimated Glomerular Filtration Rate
EPCO = European Perioperative Clinical Outcome
ESA = European Society of Anesthesiologists
et = End Tidal
Hb = Hemoglobin
HDU = High Dependency Unit
ICU = Intensive Care Unit
IQR = Interquartile Range
NE = Norepinephrine
NRS = Numeric Rating Scale
OPD = Open Pancreatoduodenectomy
Declarations

- Ethics approval and consent to participate: The Medical Ethics Committee approved a waiver for informed consent on February 14th 2019 (MEC-2019-0090, Medical Ethics Committee, Erasmus MC University Hospital, P. Box 2040, 3000 CA, Rotterdam, the Netherlands), given the retrospective nature of this observational study.

- Consent for publication: not applicable.

- Availability of data and materials: the datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

- Competing interests: the authors declare that they have no competing interests.

- Funding: departmental funding only.

- Authors’ contributions: All authors contributed to the study conception and design. Data collection and subsequent analysis were performed by AvdE. The first draft of the manuscript was written by AvdE and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

- Acknowledgements: The authors thank Khe T.C.K. Tran, MD, consultant surgeon (department of Surgery, Division of Hepatobiliary, Pancreatic- and Transplant Surgery at Erasmus University MC, Rotterdam, the Netherlands) for her help in implementing the robot-assisted pancreatoduodenectomy in our university hospital. We also acknowledge Casper H.J. van Eijck, MD, PhD, professor and consultant surgeon (department of Surgery, Division of Hepatobiliary, Pancreatic- and Transplant Surgery at Erasmus University MC, Rotterdam, the Netherlands) for leading and coordinating the pancreatic surgical team in our university hospital.

References
1. Giulianotti PC, Coratti A, Angelini M, Sbrana F, Secongi S, Balestracci T, Caravagllos G. Robotics in general surgery: personal experience in a large community hospital. Arch Surg. 2003 Jul;138(7):777–84.

2. Chen S, Chen JZ, Zhan Q, Deng XX, Shen BY, Peng CH, Li HW. Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. Surg Endosc. 2015 Dec;29(12):3698–711.

3. Boggi U, Napoli N, Costa F, Kauffmann EF, Menonna F, Iacopi S, Vistoli F, Amorese G. Robotic-assisted pancreatic resections. World J Surg. 2016 Oct;40(10):2497–506.

4. Wang SE, Shyr BU, Chen SC, Shyr YM. Comparison between robotic and open pancreaticoduodenectomy with modified Blumgart pancreaticojejunostomy: a propensity score-matched study. Surgery. 2018 Dec;164(6):1162–7.

5. Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D, Christophi C, Leslie K, McGuinness S, Parke R, Serpell J, Chan MTV, Painter T, McCluskey S, Minto G, Wallace S, Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018 Jun;378(24):2263–74.

6. Grant F, Brennan MF, Allen PJ, DeMatteo RP, Kingham P, D'Angelica M, Fisher ME, Gonen M, Zhang H, Jarnagin WR. Prospective randomized controlled trial of liberal vs restricted perioperative fluid management in patients undergoing pancreactectomy. Ann Surg. 2016 Oct;264(4):591–8.

7. Odeberg S, Ljungqvist O, Svenberg T, Gannedahl P, Bäckdahl M, von Rosen A, Sollevi A. Hemodynamic effects of pneumoperitoneum and the influence of posture during anesthesia for laparoscopic surgery. Acta Anesthesiol Scand. 1994 Apr;38(3):276–83.

8. He H, Gruartmoner G, Ince Y, van Berge Henegouwen M, Gisbertz SS, Geerts BF, Ince C, Hollmann MW, Liu D, Veelo DP. Pneumoperitoneum and steep reverse-Trendelenburg position on mean systemic filling pressure, venous return, and microcirculation during esophagectomy. J Thorac Dis. 2018 Jun;10(6):3399–408.

9. Atkinson TM, Giraud GD, Togioka BM, Jones DB, Cigarroa JE. Cardiovascular and ventilatory consequences of laparoscopic surgery. Circulation. 2017 Feb;135(7):700–10.

10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

11. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205–13.

12. Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013 Jul;258(1):1–7.

13. Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Paolo P, Leva B, Rhodes A, Hoefl A, Walder B, Chew MS, Pearse RP. European Society of Anaesthesiology (ESA) and the European Society of Intensive Care Medicine (ESICM), European Society of Anaesthesiology, European Society of Intensive Care Medicine. Standards for definitions and use of outcome measures for clinical
effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anesthesiol. 2015 Feb; 32 (2): 88-105.

14. Kim JH, Gonzalez-Heredia R, Daskalaki D, Rashdan M, Masrur M, Giulianotti PC. Totally replaced right hepatic artery in pancreaticoduodenectomy: is this anatomical condition a contraindication to minimally invasive surgery? HPB (Oxford). 2016 Jul; 18(7): 580–5.

15. Jung JP, Zenati MS, Dhir M, Zureikat AM, Zeh HJ, Simmons RL, Hogg ME. Use of video review to investigate technical factors that may be associated with delayed gastric emptying after pancreaticoduodenectomy. JAMA Surg. 2018 Oct;153(10):918–27.

16. Hurwitz EE, Simon M, Vinta SR, Zehm CF, Shabot SM, Minhajuddin A, Abouleish AE. Adding examples to the ASA-physical status classification improves correct assignment to patients. Anesthesiology. 2017 Apr;126(4):614–22.

17. Van Roessel S, Mackay TM, Van Dieren S, Van der Schelling GP, Nieuwenhuijs VB, Bosscha K, Van der Harst E, Van Dam RM, Liem MSL, Festen S, Stommel MWJ, Roos D, Wit F, Molenaar Q, De Meijer VE, Kazemier G, De Hingh IGJT, Van Santvoort HC, Bonsing BA, Busch OR, Groot Koerkamp B, Besselink MG, Dutch Pancreatic Cancer Group. Textbook outcome: nationwide analysis of a novel quality measure in pancreatic surgery. Ann Surg. 2020 Jan;271(1):155–62.

18. Bengt van Rijssen L, Groot Koerkamp B, Zwart MJ, Bonsing BA, Bosscha K, Van Dam RM, Van Eijck CH, Gerhards MF, Van der Harst E, De Hingh IH, De Jong KP, Kazemier G, Klaase J, Van Laarhoven CJ, Molenaar Q, Patijn GA, Rupert CG, Van Santvoort HC, Scheepers JJ, Van der Schelling GP, Busch OR, Besselink MG. Dutch Pancreatic Cancer Group. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford). 2017 Oct; 19(10): 919–26.

19. Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. J Intensive Care Med. 2019 Jan;34(1):26–33.

20. Tian DH, Smyth C, Keijzers G, Mackdonald SP, Peake S, Udy A, Delaney A. Safety of peripheral administration of vasopressor medications: a systematic review. Emerg M Australas. 2020 Apr;32(2):220–7.

21. Bannone E, Andrianello S, Marchegiani G, Masini G, Malleo G, Bassi C, Salvia R. Postoperative acute pancreatitis following pancreaticoduodenectomy: a determinant of fistula potentially driven by the intraoperative fluid management. Ann Surg. 2018 Nov;268(5):815–22.

22. Garland ML, Mace HS, Mac Cormick AD, McCluskey SA, Lightfoot N. Restrictive versus liberal fluid regimens in patients undergoing pancreaticoduodenectomy: a systematic review and meta-analysis. J Gastrointest Surg. 2019 Jun;23(6):1250–65.

23. Simões CM, Carmona MJC, Hajjar LA, Vincent JL, Landoni G, Belletti A. Predictors of major complications after elective abdominal surgery in cancer patients. BMC Anesthesiol. 2018 May;18(1):49.
24. De Schryver N, Wittebole X, Hubert C, Gigot JF, Laterre PF, Castanares-Zapatero D. Early hyperlactatemia predicts pancreatic fistula after surgery. BMC Anesthesiol. 2015 Jul;28(15):109.
25. Groen JV, Khawar AAJ, Bauer PA, Bonsing BA, Martini CH, Mungroop TH, Vahrmeijer AL, Vuijk J, Dahan A, Mieog JSD. Meta-analysis of epidural analgesia in patients undergoing pancreateoduodenectomy. BJS Open. 2019 Apr; 29(5): 559–571.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx
- Additionalfile2.docx
- Additionalfile3.docx